Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers.
Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of various tumors. The company was founded in 2011 and is headquartered in Suzhou, China. The company trades on NGM exchange. The company headquarter is located in Suzhou ,China.
| Ticker | ADAG |
| Long Name | Adagene Inc. |
| Short Name | Adagene Inc. |